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Oral Presentations 
fibric acid derivatives used as needed to control hyperlipidemia. 
The overall response rate was 68% (n=18), with 5 CR and 13 PR. 
Of the remaining patients, 6 failed to respond, 3 had progressive 
disease and 2 patients were not evaluable. Response by disease 
location included skin (n=17), lower GI (n=l), liver (n=l), mucosal 
(n=3), and ocular (n=2). 6/8 (75%) of patients with scleroderma 
responded. Overall, sirolimus was tolerated well, with mostly 
reversible adverse ffects which included: hypertriglyceridemia 
(22, 76%), hypereholesterolemia (8, 28%), hypertension (i6, 
55%), thrombocytopenia (11, 38%), and leukopenia (6, 21%). 
Fourteen (48%) patients remain alive, with 11 deaths occurring 
from progression of cGVHD. Overall smMval since sirolimus ini- 
tiation was 42%, (95% CI 23-61). Combination therapy with 
sirolituus and tacrolimus i  an active regimen for the treatment of 
steroid refractory cGVHD, particularly in patients with steroid- 
refractory scleroderma. Based on these preliminary findings, fur- 
ther investigation of sirolimus in combination with tacrolimus for 
the management of cGVHD is warranted. 
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DONOR PRETREATMENT WITH PROGENIPOIETIN-I PREVENTS 
ACUTE GRAFT-VERSUS-HOST DISEASE IN AN IL-IO DEPENDENT 
FASHION AND AUGMENTS THE GRAFT-VERSUS-LEUKEMIA EFFECT 
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We have studied the ability of stem cell grafts mobilised with the 
chimeric G-CSF and FLT-3 receptor agonist Progenipoietin-1 
(ProGP-1) to separate graft-versus-host disease (GVHD) and graft- 
versus-leukemia (GVL) in the well described B6 ~ B6D2F1 stem 
ceil transplant (SCT) nmdel. ProGP-1, G-CSF or control diluent 
was administered to donor B6 mice. ProGP 1 expanded all cell ine- 
ages in the spleen and blood with dramatic expansion of dendritic 
cells (DC) and granulocyte-nmnocyte lin ages (2-log increase). 
Transplant survival was 0%, 50% and 90% in recipients of control, 
G-CSF and ProGP-I treated allogeneic donor splenocytes respec- 
tively (P<0.0001). Donor pretreatment with ProGP-1 allowed a 2 to 
4-fold escalation in T cell dose over that possible with G-CSF. 
Donor CD4 T cells from allogeneic SCT recipients of ProGP 1 
splenocytes demonstrated ananergic response to host antigen (pro- 
liferation and cytokine) while CD8 T cell cytotoxicity to host anti 
gens remained intact. Neither CD1 lc hi DC nor "plasmacytoid" 
CDllc'I~m/B220 hi DC |roln ProGP-1 treated onor animals con- 
ferred protection from GVIID. Conversely, when equa] numbers of 
purified T cells from contro], G-CSF or ProGP-1 treated allogene- 
ic donors were added to allogeneic T-cell depleted control spleen, 
survival at day 60 was 0%, 15% and 90% respectively (P<0.0001). 
The improved survival in recipients of ProGP-1 T cells was associ- 
ated with reductions in systemic TNF0c generation (Control v 
ProGP-l: 227--82 v 35+14 pg/ml, P<0.01) and GVHD of the GI 
tract (senti-quantitative GVHD score: 19.5+2.1 v 9.5+0.4, P<0.01). 
Splenocytes from ProGP-1, but not control nor G-CSF treated ani- 
mals produced large amounts of IL-I0 to CpG. Furthermore, 
ProGP-1 expanded IL-lff/- splenocytes tailed to prevent GVI-ID 
relative to wild type (survival: 0% v 67%, P<0.001). In GVL experi- 
ments shown below, host type P815 was added to grafts on day 0 
and survival was monitored for 70 days after SCT. Recipients of 
ProGP-1 splenocytes containing either low or high T ceil doses rel 
ative to G-CSF had improved overall survival due to reduced 
GVtlD mortality and leukemia relapse (~P<0.05 v G-CSF). These 
data confirm that donor pretreatment with ProGP-1 prevents 
GVHD in an IL 10 and T cell dependent fashion and is superior to 
G-CSF in separating GVHD and GVL after allogeneic SCT. 
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APPLICATION OF IMMUNE-THERAPEUTIC INTERVENTIONS AFTER 
ALLOGENEIC STEM-CELL TRANSPLANTATION BASED ON MRD 
DETECTION WITH COMBINED MORPHOLOGICAL AND CYTOGENETIC 
ANALYSIS 
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Recurrent disease remains a major obstacle to cure after allo- 
geneic transplantation. Detection of MRD allows timely applica- 
tion of immune-therapeutic interventions such as early withdrawal 
of immunesuppression or DLI to those destined to relapse. We 
used a novel system (Duet-TM, BioView), which provides com- 
bined morphological and cytogenetic analysis on the same ceils 
(Leukemia 2000; 16:1413). Large numbers of cells are automati- 
cally scanned and their coordinates aved. MGG staining is 
removed and FISH is applied to the same slide. Small recipient- 
derived populations are targeted and their images relocated to 
identify their morphology. Patients (pts) are informative for Duet 
analysis if they have cytogenetic abnormalities or sex-mismatched 
donors. Thirty-five serial tests were performed in 31 leukemia pts. 
Results were retrospectively correlated with outcome. Four pts 
were counted twice due to different results at different ime- 
points. Duet detected minute recipient type populations (<5%) in 
28 tests. In ten tests recipient ceils were mostly blasts and in 18 
they were mature hematopoietie c lls (MHC). Seven of the ten pts 
with blasts relapsed, 3 had TRM before clinical relapse could be 
documented. Among the 18 pts with MHC morphology, one had 
early TRM and none of the others relapsed (P=0.002). Duet had 
increased sensitivity in detection of host population when com- 
pared with standard FISH. Duet specificity in predicting relapse 
was also superior to FISH. Seventy percent of those with recipient 
type blasts relapsed compared to 25% of those with any recipient 
population as detected by FISH with no specified morphology 
(p=0.05). We started applying this system prospectively for clinical 
decision-making. In two pts minute recipient blast-population 
(<1%) was detected 1-3 months post-transplant, hmnune-suppres- 
sion was rapidly tapered off. One pt developed GVHD 2-weeks 
later, when she had I5% blasts, and spontaneously re-entered sus- 
tained remission. The other pt progressed espite further inter- 
ventions. Identification of residual recipient-type cells as blasts 
predicts imminent relapse and these patients need additional ther- 
apy. YVhen residual recipient cells are MHC, pts can be followed 
with serial testing and need not be subjected to the hazards of 
additional therapy. 
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INTERLEUKIN-IO AND TUMOUR NECROSIS FACTOR ALPHA HAPLO- 
TYPES PREDICT TRANSPLANT RELATED MORTALITY AFTER UNRE- 
LATED DONOR STEM CELL TRANSPLANTS 
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]'here is evidence that serum levels of tumour necrosis factor- 
alpha (TNF-a) and IL-10 influence the probability of transplant 
related mortality (TRM) and acute graft versus host disease after 
HLA identical sibling stem cell transplantation (SCT). Certain 
genetic polymorphisms of these cytokines may also correlate with 
outconae of HLA matched unrelated onor SCT. We have stud- 
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